S_ry Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatinbased combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazne which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain.
Despite the high cure rate obtained with combination chemotherapy of non-seminomatous testicular germ cell tumours, the management of patients with an adverse prognosis at presentation, or of those who fail to respond to first-line chemotherapy, remains a therapeutic challenge (Horwich et al., 1993) . Most experimental protocols aimed at these poorrisk groups, which constitute about 15% of the patient population, involve intensification of chemotherapy with agents already known to be active against the disease. It may be that the addition to these regimens of a new drug with a different molecular mechanism of action would have a positive impact on the outcome of treatment.
Cell lines derived from human non-seminomatous testicular germ cell tumours are highly sensitive to cisplatin (Pera et al., 1987a; Walker et al., 1987) . The pattern of sensitivity observed in vitro appears to reflect the cliical response, as testis tumour cells are 3-10 times more sensitive to isplatin, bleomycin and etoposide than bladder cancer cells, compar- ing IC50 values (Masters et al., 1993) . These cell lines are also highly sensitive to another class of DNA-damaging agent: compounds which can alkylate the o6 position of guanine (Walker et al., 1992) . The mutagenic consequences of 06 alkylation of guanine are well described. In addition, some mammalian cells are acutely sensitive to the cytotoxic effects of compounds which generate this lesion (reviewed in Roberts, 1978) .
Temozolomide, which undergoes chemical decomposition to yield a monofunctional alkylating agent capable of binding to the 06 position of guanine, is a new anti-cancer agent which is less toxic than mitozolomide (Newlands et al., 1992) and which has the ability to cross the blood-brain barrier in mice. We compared the sensitivities to temozolomide of a series of human bladder and testicular germ cell tumour cell lines and three pairs of parent and cisplatin-resistant sublines.
MateriaL and nthods
The origins of the cell lines used in this study are shown in 
Results
The toxicity of temozolomide to four testis tumour and three bladder cancer cell lines was measured (Figure la) . Two of GCT27 was derived from a primary tumour in a patient who had not been treated with chemotherapy. In contrast, GCIT44 was derived from a metastatic lesion in a patient who had previously been treated and subsequently died of his disease.
GCT44 represents an aggressive biological variant of teratoma (Pera et al., 1987b) . Comparing the temozolomide sensitivity of three of these lines with their cisplatin-resistant sublines, the relative cross-resistance to temozolomide ranged from 1.3 for GCT27 to 2.2 for SuSa ( Figure lb and Table I ), comparing the mean concentrations reducing colony-forming ability by 50% (ICv). The sublines were derived by continuous in vitro exposure to cisplatin, and exhibit a 4-to 6-fold resitance to cisplatin, comparing doses that reduce clonogenic cell survival by 50%. Temozolomide concentration (rg mLl) Fugwe 1 Dose -response curves of testis and bladder cancer cell lines to temozolomide. Cells plated at clonal density were exposed to a range of concentrations of temozolomide, and after a further 9-15 days' culture the colony-forming ability of the treated cells was compared with that of the untreated controls. Two testis tumour cell lines were shown to be exceptionally sensitive to temozolomide. This fmding eitends our observation that testis tumour cell lines are particuly sensitive to N-nitroso-N-methylurea (MNU) and mitozolomide (Walker et al., 1992) . This earlier study also demonstrated that GCT27 is more sensitive than the other testis tumour lines studied, with IC50 values to MNU and mitozolomide of 1.2 and 0.31ggmlP', compared with 12.2 and 1.3jLgml-' for SuSa (testis) and 56.9 and 4.5JLgml-' for RT112 (bladder). The greater sensitivity of GCT27 to temozolomide, mitozolomide and MNU may be related to its low levels of o6-alkylguanine-DNA alkyltransferase activity (see Table I ). 
